文献速递白血病贫血与红细胞疾病

老年急性髓系白血病患者蒽环类相关心脏毒性:Young SIOG 综述

Anthracycline-related cardiotoxicity in older patients with acute myeloid leukemia: a Young SIOG review paper.
PubMed 文献 · Blood Adv · 2020-01-01

老年急性髓系白血病(AML)发病率随年龄增长,含阿糖胞苷和蒽环类的强化诱导化疗是数十年来的标准方案,但蒽环类显著增加心脏毒性风险,尤其蒽环类相关左心室功能障碍(ARLVD)。老年患者心脏合并症和危险因素患病率更高,可能进一步增加ARLVD风险。本文综述AML患者ARLVD的患病率、易感因素、心功能评估及管理,并讨论预防策略和替代方案的有限证据,建议基于心脏疾病、危险因素和预测化疗反应进行风险分层,蒽环类仍是诱导治疗的合适选择,但左心室射血分数下降时应考虑替代策略。

要点

  • 老年AML患者因心脏合并症多,蒽环类相关左心室功能障碍风险更高。
  • 建议治疗前综合评估心功能影像、心脏危险因素和症状以进行风险分层。
  • 蒽环类仍是诱导治疗合适选择,但左心室射血分数下降时应考虑替代策略。

核心结论

  • 基于年轻成人和非随机试验的外推,建议对老年AML患者进行综合基线心功能评估以风险分层ARLVD。
  • 蒽环类仍是诱导治疗的合适选择,但需基于心脏疾病、危险因素和预测化疗反应仔细风险分层。
  • 左心室射血分数下降时,应考虑替代蒽环类的策略。

研究设计与样本

  • 本文为Young International Society of Geriatric Oncology组的综述,聚焦老年AML患者蒽环类相关心脏毒性。

主要发现

  • 老年成人中心脏合并症和危险因素患病率更高,可能进一步增加ARLVD风险。
  • 仅少数临床试验关注左心室射血分数轻度下降或ARLVD高风险患者的替代治疗策略。
  • 预防ARLVD的策略及心脏合并症背景下替代蒽环类的证据有限。

临床怎么用

  • 治疗前应通过影像综合评估基线心功能、心脏危险因素和症状以风险分层ARLVD。
  • 诱导治疗可选用蒽环类,但需基于心脏疾病、危险因素和预测化疗反应进行风险分层。
  • 左心室射血分数下降时,应考虑替代蒽环类的治疗策略。

局限性

  • 仅少数临床试验聚焦左心室射血分数轻度下降或ARLVD高风险患者的替代策略。
  • 预防ARLVD的策略及心脏合并症背景下替代蒽环类的证据有限。
  • 建议基于年轻成人和非随机试验的外推。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The incidence of acute myeloid leukemia (AML) increases with age. Intensive induction chemotherapy containing cytarabine and an anthracycline has been part of the upfront and salvage treatment of AML for decades. Anthracyclines are associated with a significant risk of cardiotoxicity (especially anthracycline-related left ventricular dysfunction [ARLVD]). In the older adult population, the higher prevalence of cardiac comorbidities and risk factors may further increase the risk of ARLVD. In this article of the Young International Society of Geriatric Oncology group, we review the prevalence of ARLVD in patients with AML and factors predisposing to ARLVD, focusing on older adults when possible. In addition, we review the assessment of cardiac function and management of ARLVD during and after treatment. It is worth noting that only a minority of clinical trials focus on alternative treatment strategies in patients with mildly declined left ventricular ejection fraction or at a high risk for ARLVD. The limited evidence for preventive strategies to ameliorate ARLVD and alternative strategies to anthracycline use in the setting of cardiac comorbidities are discussed. Based on extrapolation of findings from younger adults and nonrandomized trials, we recommend a comprehensive baseline evaluation of cardiac function by imaging, cardiac risk factors, and symptoms to risk stratify for ARLVD. Anthracyclines remain an appropriate choice for induction although careful risk-stratification based on cardiac disease, risk factors, and predicted chemotherapy-response are warranted. In case of declined left ventricular ejection fraction, alternative strategies should be considered.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Neuendorff NR, Loh KP, Mims AS, et al. Anthracycline-related cardiotoxicity in older patients with acute myeloid leukemia: a Young SIOG review paper. Blood Adv. 2020. PMID: 32097461. doi:10.1182/bloodadvances.2019000955

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。